BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scherman Rydhög J, Irming Jølck R, Andresen TL, Munck af Rosenschöld P. Quantification and comparison of visibility and image artifacts of a new liquid fiducial marker in a lung phantom for image-guided radiation therapy: A new liquid fiducial marker for IGRT. Med Phys 2015;42:2818-26. [DOI: 10.1118/1.4919616] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 de Blanck SR, Rydhög JS, Larsen KR, Clementsen PF, Josipovic M, Aznar MC, Af Rosenschöld PM, Jølck RI, Specht L, Andresen TL, Persson GF. Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer. Clin Transl Radiat Oncol 2018;13:24-8. [PMID: 30258990 DOI: 10.1016/j.ctro.2018.07.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
2 Gorgisyan J, Lomax AJ, Rosenschold PMA, Persson GF, Krieger M, Colvill E, Scherman J, Gagnon-moisan F, Egloff M, Fattori G, Engelholm SA, Weber DC, Perrin R. The dosimetric effect of residual breath-hold motion in pencil beam scanned proton therapy – An experimental study. Radiotherapy and Oncology 2019;134:135-42. [DOI: 10.1016/j.radonc.2019.01.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Christensen AN, Rydhög JS, Søndergaard RV, Andresen TL, Holm S, Munck af Rosenschöld P, Conradsen K, Jølck RI. Injectable silver nanosensors: in vivo dosimetry for external beam radiotherapy using positron emission tomography. Nanoscale 2016;8:11002-11. [DOI: 10.1039/c6nr00201c] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
4 Rydhög JS, Mortensen SR, Larsen KR, Clementsen P, Jølck RI, Josipovic M, Aznar MC, Specht L, Andresen TL, Rosenschöld PM, Persson GF. Liquid fiducial marker performance during radiotherapy of locally advanced non small cell lung cancer. Radiother Oncol 2016;121:64-9. [PMID: 27443450 DOI: 10.1016/j.radonc.2016.06.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
5 Schaarup-Jensen H, Jensen AI, Hansen AE, El Ali HH, Hammershøj P, Jølck RI, Kjær A, Andresen TL, Clausen MH. Injectable iodine-125 labeled tissue marker for radioactive localization of non-palpable breast lesions. Acta Biomater 2018;65:197-202. [PMID: 29056556 DOI: 10.1016/j.actbio.2017.10.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
6 Maiorano G, Mele E, Frassanito MC, Restini E, Athanassiou A, Pompa PP. Ultra-efficient, widely tunable gold nanoparticle-based fiducial markers for X-ray imaging. Nanoscale 2016;8:18921-7. [PMID: 27812579 DOI: 10.1039/c6nr07021c] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
7 Scherman Rydhög J, Riisgaard de Blanck S, Josipovic M, Irming Jølck R, Larsen KR, Clementsen P, Lars Andersen T, Poulsen PR, Fredberg Persson G, Munck Af Rosenschold P. Target position uncertainty during visually guided deep-inspiration breath-hold radiotherapy in locally advanced lung cancer. Radiother Oncol 2017;123:78-84. [PMID: 28245908 DOI: 10.1016/j.radonc.2017.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
8 Schneider S, Aust DE, Brückner S, Welsch T, Hampe J, Troost EGC, Hoffmann AL. Detectability and structural stability of a liquid fiducial marker in fresh ex vivo pancreas tumour resection specimens on CT and 3T MRI. Strahlenther Onkol 2019;195:756-63. [PMID: 31143995 DOI: 10.1007/s00066-019-01474-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Brown KH, Ghita M, Schettino G, Prise KM, Butterworth KT. Evaluation of a Novel Liquid Fiducial Marker, BioXmark®, for Small Animal Image-Guided Radiotherapy Applications. Cancers (Basel) 2020;12:E1276. [PMID: 32443537 DOI: 10.3390/cancers12051276] [Reference Citation Analysis]
10 Osman SOS, Russell E, King RB, Crowther K, Jain S, McGrath C, Hounsell AR, Prise KM, McGarry CK. Fiducial markers visibility and artefacts in prostate cancer radiotherapy multi-modality imaging. Radiat Oncol 2019;14:237. [PMID: 31878967 DOI: 10.1186/s13014-019-1447-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
11 Steybe D, Poxleitner P, Voss PJ, Metzger MC, Schmelzeisen R, Bamberg F, Kim S, Russe MF. Evaluation of computed tomography settings in the context of visualization and discrimination of low dose injections of a novel liquid soft tissue fiducial marker in head and neck imaging. BMC Med Imaging 2021;21:157. [PMID: 34702192 DOI: 10.1186/s12880-021-00689-y] [Reference Citation Analysis]
12 Machiels M, Voncken FEM, Jin P, van Dieren JM, Bartels-Rutten A, Alderliesten T, Aleman BMP, van Hooft JE, Hulshof MCCM. A Novel Liquid Fiducial Marker in Esophageal Cancer Image Guided Radiation Therapy: Technical Feasibility and Visibility on Imaging. Pract Radiat Oncol 2019;9:e506-15. [PMID: 31279938 DOI: 10.1016/j.prro.2019.06.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
13 Izatt MT, Lees D, Mills S, Grant CA, Little JP. Determining a reliably visible and inexpensive surface fiducial marker for use in MRI: a research study in a busy Australian Radiology Department. BMJ Open 2019;9:e027020. [PMID: 31375607 DOI: 10.1136/bmjopen-2018-027020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Scherman Rydhög J, Perrin R, Jølck RI, Gagnon-Moisan F, Larsen KR, Clementsen P, Riisgaard de Blanck S, Fredberg Persson G, Weber DC, Lomax T, Andresen TL, Munck Af Rosenschold P. Liquid fiducial marker applicability in proton therapy of locally advanced lung cancer. Radiother Oncol 2017;122:393-9. [PMID: 28104299 DOI: 10.1016/j.radonc.2016.12.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
15 Hansen AE, Henriksen JR, Jølck RI, Fliedner FP, Bruun LM, Scherman J, Jensen AI, Munck Af Rosenschöld P, Moorman L, Kurbegovic S, de Blanck SR, Larsen KR, Clementsen PF, Christensen AN, Clausen MH, Wang W, Kempen P, Christensen M, Viby NE, Persson G, Larsen R, Conradsen K, McEvoy FJ, Kjaer A, Eriksen T, Andresen TL. Multimodal soft tissue markers for bridging high-resolution diagnostic imaging with therapeutic intervention. Sci Adv 2020;6:eabb5353. [PMID: 32875113 DOI: 10.1126/sciadv.abb5353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 de Ridder M, Gerbrandy LC, de Reijke TM, Hinnen KA, Hulshof MCCM. BioXmark® liquid fiducial markers for image-guided radiotherapy in muscle invasive bladder cancer: a safety and performance trial. Br J Radiol 2020;93:20200241. [PMID: 32463291 DOI: 10.1259/bjr.20200241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Ogino I, Kitagawa M, Watanabe S, Yoshida H, Hata M. Calcium Phosphate Cement Paste Injection as a Fiducial Marker of Cervical Cancer. In Vivo 2018;32:1609-15. [PMID: 30348723 DOI: 10.21873/invivo.11421] [Reference Citation Analysis]
18 Wang T, Inubushi S, Ikeo N, Mukai T, Okumura K, Akasaka H, Yada R, Yoshida K, Miyawaki D, Ishihara T, Nakaoka A, Sasaki R. Novel artifact-robust and highly visible zinc solid fiducial marker for kilovoltage x-ray image-guided radiation therapy. Med Phys 2020;47:4703-10. [PMID: 32696571 DOI: 10.1002/mp.14412] [Reference Citation Analysis]
19 De Roover R, Crijns W, Poels K, Peeters R, Draulans C, Haustermans K, Depuydt T. Characterization of a novel liquid fiducial marker for multimodal image guidance in stereotactic body radiotherapy of prostate cancer. Med Phys 2018;45:2205-17. [PMID: 29537613 DOI: 10.1002/mp.12860] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
20 Dobiasch S, Kampfer S, Burkhardt R, Schilling D, Schmid TE, Wilkens JJ, Combs SE. BioXmark for high-precision radiotherapy in an orthotopic pancreatic tumor mouse model : Experiences with a liquid fiducial marker. Strahlenther Onkol 2017;193:1039-47. [PMID: 28808749 DOI: 10.1007/s00066-017-1193-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
21 Schneider S, Jølck RI, Troost EGC, Hoffmann AL. Quantification of MRI visibility and artifacts at 3T of liquid fiducial marker in a pancreas tissue-mimicking phantom. Med Phys 2018;45:37-47. [DOI: 10.1002/mp.12670] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
22 Steybe D, Russe MF, Ludwig U, Sprave T, Vach K, Semper-Hogg W, Schmelzeisen R, Voss PJ, Poxleitner P. Intraoperative marking of the tumour resection surface for improved radiation therapy planning in head and neck cancer: preclinical evaluation of a novel liquid fiducial marker. Dentomaxillofac Radiol 2021;50:20200290. [PMID: 32915672 DOI: 10.1259/dmfr.20200290] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]